Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Hydratec Industries NV is a technology company and industrial holding that develops, produces, and supplies high-quality industrial systems and hightech plastic components tailored to the needs of food, health, and mobility sectors. Its core activities span two main segments: Industrial Systems, which focuses on project-based manufacturing of complete systems under brands like Lan, Royal Pas Reform, and Rollepaal, including sterilized product handling, automated packaging solutions for food in pouches, tins, jars, bags, nets, boxes, and crates, as well as industrial incubators, hatchery automation, climate control equipment, and hatchery management software; and Hightech Components, encompassing extrusion equipment for pipes, plastic injection molding for climate systems, vehicles, bicycles, and coffee machines, plus rubber, metal, and plastic precision parts such as dosing systems, braking components, and medical cartridges via subsidiaries like Helvoet and Timmerije. Serving markets across the Netherlands, Europe, North America, Asia, South America, Africa, and Oceania, Hydratec Industries NV contributes to efficient food production, advanced healthcare solutions, and sustainable mobility through lightweight, functional components that reduce emissions. Founded in the Netherlands and headquartered in Amersfoort, it operates through specialized subsidiaries to deliver innovative engineering for global industries.
11.81% operating margin is respectable but not wide. ROIC at 18.73%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 2.6% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€263M
▼ -2.6% YoY
Net Income (TTM)
€24M
▲ +32.2% YoY
Op. Margin
11.81%
▲ +2.4pp YoY
ROIC
18.73%
▲ +2.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€29M
▼ -6.5% YoY
Op. Cash Flow (TTM)
€33M
▼ -13.2% YoY
Net Debt
-€12M
Net Cash Position
Cash & Equiv.
€25M
3Y CAGR: -2.4%
3Y CAGR: -4.2%
Continue Research